Anlotinib Combined With Whole-Brain Radiotherapy in Non-Small Cell Lung Cancer With Multiple Brain Metastases That Progressed or Developed After At Least One Lines of Prior Treatment

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Anlotinib Combined With Whole-Brain Radiotherapy in Non-Small Cell Lung Cancer With Multiple Brain Metastases That Progressed or Developed After At Least One Lines of Prior Treatment

header-info

Sep, 18, 2023

According to results of this retrospective study, anlotinib plus whole-brain radiotherapy is a safe and effective chemotherapy-free treatment option for patients with advanced non-small cell lung cancer with multiple brain metastases that have progressed or developed after standard systemic treatment.

Access the full article to read more here.